iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference#United_States#cancer_therapy#San_Francisco#iOnctura#roginolisib
iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference
Catherine Pickering, CEO of iOnctura, will discuss the company's innovative cancer therapies at the upcoming J.P. Morgan Healthcare Conference in January.
third-news.com
January 9, 2026 at 1:12 PM
iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference#United_States#cancer_therapy#San_Francisco#iOnctura#roginolisib
iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial#Switzerland#Geneva#Myelofibrosis#roginolisib#ASH2025
iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial
iOnctura announces the initiation of its Phase I/II trial evaluating roginolisib for myelofibrosis patients not responding to JAK inhibitors.
third-news.com
December 4, 2025 at 8:12 AM
iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial#Switzerland#Geneva#Myelofibrosis#roginolisib#ASH2025
Two biotech startups, iOnctura and ImmunOs, reported positive results from ongoing Phase 1 trials for cancer therapies. Meanwhile, Reconnect Labs advanced to a Phase 2 trial for a treatment targeting sleep disturbances tied to post-traumatic stress disorder, enrolling its 1st patient. bit.ly/47Kbsc7
October 28, 2025 at 5:56 PM
Two biotech startups, iOnctura and ImmunOs, reported positive results from ongoing Phase 1 trials for cancer therapies. Meanwhile, Reconnect Labs advanced to a Phase 2 trial for a treatment targeting sleep disturbances tied to post-traumatic stress disorder, enrolling its 1st patient. bit.ly/47Kbsc7
iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with pancreatic cancer at ESMO
www.viv-media.com/infozx-37700...
www.viv-media.com/infozx-37700...
iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with pancreatic cancer at ESMO
www.viv-media.com
October 14, 2025 at 12:41 PM
iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with pancreatic cancer at ESMO
www.viv-media.com/infozx-37700...
www.viv-media.com/infozx-37700...
iOnctura's cambritaxestat Shows Potent Efficacy in Pancreatic Cancer at ESMO#None#Berlin#pancreatic_cancer#iOnctura#cambritaxestat
iOnctura's cambritaxestat Shows Potent Efficacy in Pancreatic Cancer at ESMO
iOnctura has presented promising clinical data on cambritaxestat, showcasing its efficacy in treating metastatic pancreatic cancer at ESMO 2025.
third-news.com
October 14, 2025 at 8:35 AM
iOnctura's cambritaxestat Shows Potent Efficacy in Pancreatic Cancer at ESMO#None#Berlin#pancreatic_cancer#iOnctura#cambritaxestat
Hope on the horizon: iOnctura expands its Phase II roginolisib trial into the US, enrolling patients with metastatic uveal melanoma.
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
September 19, 2025 at 6:03 PM
Hope on the horizon: iOnctura expands its Phase II roginolisib trial into the US, enrolling patients with metastatic uveal melanoma.
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
September 9, 2025 at 8:26 AM
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options#United_States#Cambridge#oncology#iOnctura#roginolisib
iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options
iOnctura's expansion of roginolisib trials to the US aims to revolutionize cancer treatment strategies for hard-to-treat cancers.
third-news.com
September 9, 2025 at 7:16 AM
iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options#United_States#Cambridge#oncology#iOnctura#roginolisib
iOnctura Welcomes Two Experienced Non-Executive Directors to Board for Growth#None#Amsterdam#iOnctura#Neil_Gallagher#Anthony_Mancini
iOnctura Welcomes Two Experienced Non-Executive Directors to Board for Growth
iOnctura adds significant expertise with the appointment of two Non-Executive Directors, enhancing its oncology drug development and commercialization efforts.
third-news.com
July 24, 2025 at 8:10 AM
iOnctura Welcomes Two Experienced Non-Executive Directors to Board for Growth#None#Amsterdam#iOnctura#Neil_Gallagher#Anthony_Mancini
The results showing the benefit of combining the non-ATP competitive Pi3Kδ inhibitor roginolisib with venetoclax in lymphoid tumors are out in Haematologica. A collaboration of @iorbellinzona.bsky.social, Jennifer Brown’s group and iOnctura colleagues. haematologica.org/newsletter/v...
Early View
| Haematologica
haematologica.org
June 20, 2025 at 5:37 AM
The results showing the benefit of combining the non-ATP competitive Pi3Kδ inhibitor roginolisib with venetoclax in lymphoid tumors are out in Haematologica. A collaboration of @iorbellinzona.bsky.social, Jennifer Brown’s group and iOnctura colleagues. haematologica.org/newsletter/v...
Its been a busy week in the industry from Amber Implants announcing the results of its 1yr follow-up data for VCFix to appointments with iOnctura bolstering its leadership team, and Asgard Therapeutics and Commit Biologics strengthening their advisory boards #OptimumNewsletter ⬇️
Weekly roundup: June kickstarts with an abundance of appointments – Optimum Strategic CommunicationsLink to: Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Boar...
www.optimumcomms.com
June 6, 2025 at 12:08 PM
Its been a busy week in the industry from Amber Implants announcing the results of its 1yr follow-up data for VCFix to appointments with iOnctura bolstering its leadership team, and Asgard Therapeutics and Commit Biologics strengthening their advisory boards #OptimumNewsletter ⬇️
Thoughts on this? >> iOnctura bolsters leadership team with new
appointments >> Comment below! #industry40 #AI #healthtech #mhealth #IoT
appointments >> Comment below! #industry40 #AI #healthtech #mhealth #IoT
iOnctura bolsters leadership team with new
appointments
Steven Sciuto joins as Chief Financial Officer (CFO) bringing a wealth of experience in scaling finance functions as well as in private and public financings Michelle Tsai PharmD, with deep expertise in portfolio strategy and lifecycle planning, joins as Chief Operating Officer (COO) GENEVA, Switzerland and AMSTERDAM, The Netherlands, June 2, 2025 /PRNewswire/ — iOnctura, a …
dlvr.it
June 2, 2025 at 9:03 AM
Thoughts on this? >> iOnctura bolsters leadership team with new
appointments >> Comment below! #industry40 #AI #healthtech #mhealth #IoT
appointments >> Comment below! #industry40 #AI #healthtech #mhealth #IoT
iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations#oncology#Netherlands#Amsterdam#iOnctura#roginolisib
iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations
iOnctura announces the appointment of Steven Sciuto as CFO and Michelle Tsai as COO, enhancing leadership to boost oncology portfolio success.
third-news.com
June 2, 2025 at 7:32 AM
iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations#oncology#Netherlands#Amsterdam#iOnctura#roginolisib
From Alchemab’s landmark $415m licensing agreement with Eli Lilly & Co to clinical milestones from iOnctura and Vesper Bio, Optimum’s clients have had a busy week! Never miss industry news and subscribe today ⬇️
#OptimumsNewsletter #HealthcareCommunications
#OptimumsNewsletter #HealthcareCommunications
Weekly roundup: A multi-million dollar deal with Lilly and industry advances – Optimum Strategic CommunicationsLink to: Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate ...
www.optimumcomms.com
May 9, 2025 at 1:27 PM
From Alchemab’s landmark $415m licensing agreement with Eli Lilly & Co to clinical milestones from iOnctura and Vesper Bio, Optimum’s clients have had a busy week! Never miss industry news and subscribe today ⬇️
#OptimumsNewsletter #HealthcareCommunications
#OptimumsNewsletter #HealthcareCommunications
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
www.viv-media.com/infozx-36969...
www.viv-media.com/infozx-36969...
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
www.viv-media.com
May 8, 2025 at 1:06 PM
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
www.viv-media.com/infozx-36969...
www.viv-media.com/infozx-36969...
iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib#Netherlands#Amsterdam#Lung_Cancer#iOnctura#roginolisib
iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib
iOnctura has initiated a Phase I/II study targeting advanced non-small cell lung cancer, exploring the effectiveness of roginolisib combined with dostarlimab and chemotherapy.
third-news.com
May 8, 2025 at 8:08 AM
iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib#Netherlands#Amsterdam#Lung_Cancer#iOnctura#roginolisib
iOnctura commences randomized Phase II study in metastatic uveal melanoma
👉 Read the press release here: https://lnkd.in/ekMMhJnS
👉Details of the OCULE-01 study: https://lnkd.in/ezQFQVYr
https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2025/03/iOnctura-FPI-v3-FINAL-20.03.25-Clean.pdf
👉 Read the press release here: https://lnkd.in/ekMMhJnS
👉Details of the OCULE-01 study: https://lnkd.in/ezQFQVYr
https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2025/03/iOnctura-FPI-v3-FINAL-20.03.25-Clean.pdf
March 20, 2025 at 7:02 PM
iOnctura commences randomized Phase II study in metastatic uveal melanoma
👉 Read the press release here: https://lnkd.in/ekMMhJnS
👉Details of the OCULE-01 study: https://lnkd.in/ezQFQVYr
https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2025/03/iOnctura-FPI-v3-FINAL-20.03.25-Clean.pdf
👉 Read the press release here: https://lnkd.in/ekMMhJnS
👉Details of the OCULE-01 study: https://lnkd.in/ezQFQVYr
https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2025/03/iOnctura-FPI-v3-FINAL-20.03.25-Clean.pdf
iOnctura commences randomized Phase II study in metastatic uveal melanoma
www.viv-media.com/infozx-36525...
www.viv-media.com/infozx-36525...
iOnctura commences randomized Phase II study in metastatic uveal melanoma
www.viv-media.com
March 20, 2025 at 1:48 PM
iOnctura commences randomized Phase II study in metastatic uveal melanoma
www.viv-media.com/infozx-36525...
www.viv-media.com/infozx-36525...
iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment#None#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment
iOnctura has initiated a Phase II study for roginolisib, aimed at treating metastatic uveal melanoma, garnering orphan drug designation in Europe.
third-news.com
March 20, 2025 at 10:39 AM
iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment#None#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair
www.viv-media.com/infozx-36462...
www.viv-media.com/infozx-36462...
iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair
www.viv-media.com
March 17, 2025 at 2:15 PM
iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair
www.viv-media.com/infozx-36462...
www.viv-media.com/infozx-36462...
iOnctura Fortifies Executive Team with New CBO and Board Chair Appointments#Amsterdam#iOnctura#Elizabeth_Holt#Mark_Velleca#The_Netherlands
iOnctura Fortifies Executive Team with New CBO and Board Chair Appointments
iOnctura enhances its leadership team with the appointments of Elizabeth Holt as Chief Business Officer and Dr. Mark Velleca as Board Chair, signaling a strategic move forward.
third-news.com
March 17, 2025 at 9:09 AM
iOnctura Fortifies Executive Team with New CBO and Board Chair Appointments#Amsterdam#iOnctura#Elizabeth_Holt#Mark_Velleca#The_Netherlands
#iOnctura #uvealmelanoma #uvealmelanomapatients #uvealmelanomatherapy #phase1study #roginolisib #phase1#DIONE01study #clinicalactivity #longtermsafety #ESMO #EuropeanSocietyforMedicalOncology #ImmunoOncology #allostericbindingmechanism #phase2study #OCULE01study
pharmatimes.com/news/ionctur...
pharmatimes.com/news/ionctur...
iOnctura achieves new clinical milestones in uveal melanoma therapy - PharmaTimes
Successful phase 1 study highlights potential of roginolisib
pharmatimes.com
December 11, 2024 at 2:05 PM
iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment#Netherlands#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment
iOnctura has announced promising clinical results for roginolisib, a new treatment for uveal melanoma, showing improved survival rates.
third-news.com
December 11, 2024 at 10:42 AM
iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment#Netherlands#Amsterdam#iOnctura#roginolisib#uveal_melanoma
🚨 New publication alert! 🚨
Excited to share that first-in-class autotaxin inhibitor IOA-289 disrupts tumour-supporting signals in the pancreatic cancer TME.
Our colleagues published this study in collaboration with our portfolio company, iOnctura🌟
📰 Read more here: bit.ly/4f3RXvM
#OnMyHorizon
Excited to share that first-in-class autotaxin inhibitor IOA-289 disrupts tumour-supporting signals in the pancreatic cancer TME.
Our colleagues published this study in collaboration with our portfolio company, iOnctura🌟
📰 Read more here: bit.ly/4f3RXvM
#OnMyHorizon
December 9, 2024 at 3:43 PM
🚨 New publication alert! 🚨
Excited to share that first-in-class autotaxin inhibitor IOA-289 disrupts tumour-supporting signals in the pancreatic cancer TME.
Our colleagues published this study in collaboration with our portfolio company, iOnctura🌟
📰 Read more here: bit.ly/4f3RXvM
#OnMyHorizon
Excited to share that first-in-class autotaxin inhibitor IOA-289 disrupts tumour-supporting signals in the pancreatic cancer TME.
Our colleagues published this study in collaboration with our portfolio company, iOnctura🌟
📰 Read more here: bit.ly/4f3RXvM
#OnMyHorizon
Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura
Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura
German Merck, fresh off it and partner Pfizer’s FDA approval for their checkpoint inhibitor Bavencio, and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.
www.fiercebiotech.com
February 4, 2026 at 2:03 PM
Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura